Following its failure in pancreatic cancer (#msg-167645887), TYME became a shell company with significant cash (#msg-168370010); hence, this buyout is essentially a financing transaction for SYRS. The deal value (excluding a separate financing transaction by SYRS announced today) is about $70M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”